Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: A phase II Southwest Oncology Group study (S9504)

David R Gandara, Kari Chansky, Kathy S. Albain, Laurie E. Gaspar, Primo N Lara, Karen Kelly, John Crowley, Robert Livingston

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Purpose: Here we report 5-year survival data from S9504, a Southwest Oncology Group phase II trial evaluating consolidation docetaxel after concurrent cisplatin/etoposide and thoracic radiation therapy in patients with pathologically documented stage IIIB non-small-cell lung cancer. Survival outcomes were compared with a predecessor study (S9019) with identical eligibility, staging criteria, and treatment, excepting docetaxel consolidation. Patients and methods: Treatment consisted of cisplatin 50 mg/m2 per day on days 1, 8, 29, and 36; etoposide 50 mg/m2 per day on days 1-5 and 29-33; and concurrent thoracic radiation therapy (total dose, 61 Gy). Consolidation docetaxel (75 mg/m2 initial dose) started 4-6 weeks after completion of chemotherapy. Results: Concurrent chemotherapy was generally well tolerated, with a low level of radiation-related esophagitis; 2 patients died from pneumonitis. Grade 3/4 neutropenia during consolidation docetaxel was common. At a median follow-up of 71 months, median progression-free survival was 16 months; median survival 26 months; and 3-, 4-, and 5-year survival rates were 40%, 29%, and 29%, respectively. Brain metastasis was the most common site of failure. In the predecessor trial S9019, median survival was 15 months, and 3-, 4-, and 5-year survival rates were 17%, 17%, and 17%, respectively. Conclusion: The 5-year survival rate in S9540 of 29% compares favorably with the predecessor trial S9019 and other treatment approaches currently used in this patient population. A phase III trial designed to validate the concept of consolidation docetaxel is presently under way.

Original languageEnglish (US)
Pages (from-to)116-121
Number of pages6
JournalClinical Lung Cancer
Volume8
Issue number2
StatePublished - Sep 2006

Fingerprint

docetaxel
Non-Small Cell Lung Carcinoma
Survival
Survival Rate
Etoposide
Cisplatin
Radiotherapy
Thorax
Therapeutics
Drug Therapy
Esophagitis
Neutropenia
Disease-Free Survival
Pneumonia
Radiation
Neoplasm Metastasis
Brain

Keywords

  • Cisplatin
  • Esophagitis
  • Etoposide
  • Pneumonitis

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer : A phase II Southwest Oncology Group study (S9504). / Gandara, David R; Chansky, Kari; Albain, Kathy S.; Gaspar, Laurie E.; Lara, Primo N; Kelly, Karen; Crowley, John; Livingston, Robert.

In: Clinical Lung Cancer, Vol. 8, No. 2, 09.2006, p. 116-121.

Research output: Contribution to journalArticle

@article{b576154dce88496e80d6e3fd3773380f,
title = "Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: A phase II Southwest Oncology Group study (S9504)",
abstract = "Purpose: Here we report 5-year survival data from S9504, a Southwest Oncology Group phase II trial evaluating consolidation docetaxel after concurrent cisplatin/etoposide and thoracic radiation therapy in patients with pathologically documented stage IIIB non-small-cell lung cancer. Survival outcomes were compared with a predecessor study (S9019) with identical eligibility, staging criteria, and treatment, excepting docetaxel consolidation. Patients and methods: Treatment consisted of cisplatin 50 mg/m2 per day on days 1, 8, 29, and 36; etoposide 50 mg/m2 per day on days 1-5 and 29-33; and concurrent thoracic radiation therapy (total dose, 61 Gy). Consolidation docetaxel (75 mg/m2 initial dose) started 4-6 weeks after completion of chemotherapy. Results: Concurrent chemotherapy was generally well tolerated, with a low level of radiation-related esophagitis; 2 patients died from pneumonitis. Grade 3/4 neutropenia during consolidation docetaxel was common. At a median follow-up of 71 months, median progression-free survival was 16 months; median survival 26 months; and 3-, 4-, and 5-year survival rates were 40{\%}, 29{\%}, and 29{\%}, respectively. Brain metastasis was the most common site of failure. In the predecessor trial S9019, median survival was 15 months, and 3-, 4-, and 5-year survival rates were 17{\%}, 17{\%}, and 17{\%}, respectively. Conclusion: The 5-year survival rate in S9540 of 29{\%} compares favorably with the predecessor trial S9019 and other treatment approaches currently used in this patient population. A phase III trial designed to validate the concept of consolidation docetaxel is presently under way.",
keywords = "Cisplatin, Esophagitis, Etoposide, Pneumonitis",
author = "Gandara, {David R} and Kari Chansky and Albain, {Kathy S.} and Gaspar, {Laurie E.} and Lara, {Primo N} and Karen Kelly and John Crowley and Robert Livingston",
year = "2006",
month = "9",
language = "English (US)",
volume = "8",
pages = "116--121",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer

T2 - A phase II Southwest Oncology Group study (S9504)

AU - Gandara, David R

AU - Chansky, Kari

AU - Albain, Kathy S.

AU - Gaspar, Laurie E.

AU - Lara, Primo N

AU - Kelly, Karen

AU - Crowley, John

AU - Livingston, Robert

PY - 2006/9

Y1 - 2006/9

N2 - Purpose: Here we report 5-year survival data from S9504, a Southwest Oncology Group phase II trial evaluating consolidation docetaxel after concurrent cisplatin/etoposide and thoracic radiation therapy in patients with pathologically documented stage IIIB non-small-cell lung cancer. Survival outcomes were compared with a predecessor study (S9019) with identical eligibility, staging criteria, and treatment, excepting docetaxel consolidation. Patients and methods: Treatment consisted of cisplatin 50 mg/m2 per day on days 1, 8, 29, and 36; etoposide 50 mg/m2 per day on days 1-5 and 29-33; and concurrent thoracic radiation therapy (total dose, 61 Gy). Consolidation docetaxel (75 mg/m2 initial dose) started 4-6 weeks after completion of chemotherapy. Results: Concurrent chemotherapy was generally well tolerated, with a low level of radiation-related esophagitis; 2 patients died from pneumonitis. Grade 3/4 neutropenia during consolidation docetaxel was common. At a median follow-up of 71 months, median progression-free survival was 16 months; median survival 26 months; and 3-, 4-, and 5-year survival rates were 40%, 29%, and 29%, respectively. Brain metastasis was the most common site of failure. In the predecessor trial S9019, median survival was 15 months, and 3-, 4-, and 5-year survival rates were 17%, 17%, and 17%, respectively. Conclusion: The 5-year survival rate in S9540 of 29% compares favorably with the predecessor trial S9019 and other treatment approaches currently used in this patient population. A phase III trial designed to validate the concept of consolidation docetaxel is presently under way.

AB - Purpose: Here we report 5-year survival data from S9504, a Southwest Oncology Group phase II trial evaluating consolidation docetaxel after concurrent cisplatin/etoposide and thoracic radiation therapy in patients with pathologically documented stage IIIB non-small-cell lung cancer. Survival outcomes were compared with a predecessor study (S9019) with identical eligibility, staging criteria, and treatment, excepting docetaxel consolidation. Patients and methods: Treatment consisted of cisplatin 50 mg/m2 per day on days 1, 8, 29, and 36; etoposide 50 mg/m2 per day on days 1-5 and 29-33; and concurrent thoracic radiation therapy (total dose, 61 Gy). Consolidation docetaxel (75 mg/m2 initial dose) started 4-6 weeks after completion of chemotherapy. Results: Concurrent chemotherapy was generally well tolerated, with a low level of radiation-related esophagitis; 2 patients died from pneumonitis. Grade 3/4 neutropenia during consolidation docetaxel was common. At a median follow-up of 71 months, median progression-free survival was 16 months; median survival 26 months; and 3-, 4-, and 5-year survival rates were 40%, 29%, and 29%, respectively. Brain metastasis was the most common site of failure. In the predecessor trial S9019, median survival was 15 months, and 3-, 4-, and 5-year survival rates were 17%, 17%, and 17%, respectively. Conclusion: The 5-year survival rate in S9540 of 29% compares favorably with the predecessor trial S9019 and other treatment approaches currently used in this patient population. A phase III trial designed to validate the concept of consolidation docetaxel is presently under way.

KW - Cisplatin

KW - Esophagitis

KW - Etoposide

KW - Pneumonitis

UR - http://www.scopus.com/inward/record.url?scp=33750188024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750188024&partnerID=8YFLogxK

M3 - Article

C2 - 17026812

AN - SCOPUS:33750188024

VL - 8

SP - 116

EP - 121

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -